377 related articles for article (PubMed ID: 33827629)
1. Targeting neddylation E2s: a novel therapeutic strategy in cancer.
Zheng YC; Guo YJ; Wang B; Wang C; Mamun MAA; Gao Y; Liu HM
J Hematol Oncol; 2021 Apr; 14(1):57. PubMed ID: 33827629
[TBL] [Abstract][Full Text] [Related]
2. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
Zhou H; Lu J; Yang CY; Sun Y; Wang S
Adv Exp Med Biol; 2020; 1217():349-362. PubMed ID: 31898237
[TBL] [Abstract][Full Text] [Related]
3. NEDD8-conjugating enzyme E2s: critical targets for cancer therapy.
Zhou L; Lin X; Zhu J; Zhang L; Chen S; Yang H; Jia L; Chen B
Cell Death Discov; 2023 Jan; 9(1):23. PubMed ID: 36690633
[TBL] [Abstract][Full Text] [Related]
4. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.
Zhou W; Xu J; Tan M; Li H; Li H; Wei W; Sun Y
Mol Cell; 2018 Jun; 70(6):1008-1024.e6. PubMed ID: 29932898
[TBL] [Abstract][Full Text] [Related]
5. Discovery of neddylation E2s inhibitors with therapeutic activity.
Mamun M; Liu Y; Geng YP; Zheng YC; Gao Y; Sun JG; Zhao LF; Zhao LJ; Liu HM
Oncogenesis; 2023 Sep; 12(1):45. PubMed ID: 37717015
[TBL] [Abstract][Full Text] [Related]
6. Neddylation-CRLs regulate the functions of Treg immune cells.
Wu D; Sun Y
Bioessays; 2023 Apr; 45(4):e2200222. PubMed ID: 36709423
[TBL] [Abstract][Full Text] [Related]
7. Micafungin: A promising inhibitor of UBE2M in cancer cell growth suppression.
Mamun MAA; Liu S; Zhao L; Zhao L; Li ZR; Shen D; Zheng Y; Zheng YC; Liu HM
Eur J Med Chem; 2023 Nov; 260():115732. PubMed ID: 37651876
[TBL] [Abstract][Full Text] [Related]
8. SENP8 limits aberrant neddylation of NEDD8 pathway components to promote cullin-RING ubiquitin ligase function.
Coleman KE; Békés M; Chapman JR; Crist SB; Jones MJ; Ueberheide BM; Huang TT
Elife; 2017 May; 6():. PubMed ID: 28475037
[TBL] [Abstract][Full Text] [Related]
9. Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity.
Zhou L; Zhu J; Chen W; Jiang Y; Hu T; Wang Y; Ye X; Zhan M; Ji C; Xu Z; Wang X; Gu Y; Jia L
Cell Death Dis; 2020 Nov; 11(11):975. PubMed ID: 33184273
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers.
Yin L; Xue Y; Shang Q; Zhu H; Liu M; Liu Y; Hu Q
Curr Top Med Chem; 2019; 19(12):1059-1069. PubMed ID: 30854973
[TBL] [Abstract][Full Text] [Related]
11. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
12. Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.
Hammill JT; Scott DC; Min J; Connelly MC; Holbrook G; Zhu F; Matheny A; Yang L; Singh B; Schulman BA; Guy RK
J Med Chem; 2018 Apr; 61(7):2680-2693. PubMed ID: 29547696
[TBL] [Abstract][Full Text] [Related]
13. Inactivating UBE2M impacts the DNA damage response and genome integrity involving multiple cullin ligases.
Cukras S; Morffy N; Ohn T; Kee Y
PLoS One; 2014; 9(7):e101844. PubMed ID: 25025768
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of Nedd8‑conjugating enzyme UBE2M suppresses the proliferation and induces the apoptosis of intrahepatic cholangiocarcinoma cells.
Zhao B; Gao C; Shi D; Mao J; Zhao J; Guo L; Guo J; Jiao Z
Oncol Rep; 2019 Dec; 42(6):2670-2679. PubMed ID: 31545502
[TBL] [Abstract][Full Text] [Related]
15. Diverse and pivotal roles of neddylation in metabolism and immunity.
Zou T; Zhang J
FEBS J; 2021 Jul; 288(13):3884-3912. PubMed ID: 33025631
[TBL] [Abstract][Full Text] [Related]
16. NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Zhao X; Jiang L; Hu D; Tang Y; Zhao G; Du X; Luo S; Tang W
Exp Cell Res; 2021 Jun; 403(2):112614. PubMed ID: 33905671
[TBL] [Abstract][Full Text] [Related]
17. Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.
Zhou W; Ma L; Ding L; Guo Q; He Z; Yang J; Qiao H; Li L; Yang J; Yu S; Zhao L; Wang S; Liu HM; Suo Z; Zhao W
J Med Chem; 2019 Jun; 62(11):5382-5403. PubMed ID: 31157974
[TBL] [Abstract][Full Text] [Related]
18. Protein neddylation and its role in health and diseases.
Zhang S; Yu Q; Li Z; Zhao Y; Sun Y
Signal Transduct Target Ther; 2024 Apr; 9(1):85. PubMed ID: 38575611
[TBL] [Abstract][Full Text] [Related]
19. Improvement of Oral Bioavailability of Pyrazolo-Pyridone Inhibitors of the Interaction of DCN1/2 and UBE2M.
Kim HS; Hammill JT; Scott DC; Chen Y; Rice AL; Pistel W; Singh B; Schulman BA; Guy RK
J Med Chem; 2021 May; 64(9):5850-5862. PubMed ID: 33945681
[TBL] [Abstract][Full Text] [Related]
20. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
